drugset
drugset / Trial / NCT01331616

Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab

NCT01331616 ↗

Phase 0 Withdrawn West Penn Allegheny Health System
NaSingle-groupOpen-labelTreatment

Summary

Does treatment with bevacizumab (Avastin) in combination with prior or current radiotherapy lead to optic neuropathy?

Timeline

Start
2011-03
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg —

Indications

glioblastoma optic nerve disorder